Skip to content
OpenCapital
Get started

United Therapeutics UTHR Q2 2025 earnings

Reported July 30, 2025 · Before market open

Revenue$798.6MMiss by $3.3MDiluted EPS$6.41Miss by $0.88
Revenue estimate$801.9M
EPS estimate$7.29

Next report

Jul 29, 2026 (In 4 days)
Revenue estimate$805.0M
EPS estimate$7.06

Financials

Q2 2025

Income statement

See full
Revenue$798.6M+11.7%
Gross profit$711.0M+11.6%
Operating income$364.5M+13.9%
Net income$309.5M+11.3%
EPS (diluted)$6.41+9.6%

Balance sheet

See full
Cash & equivalents$1.6B+17.5%
Total equity$7.2B+25.9%
Total assets$7.9B+17.6%

Cash flow

See full
Operating cash flow$191.7M-17.4%
CapEx$62.2M+37.9%
Free cash flow$129.5M-30.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$13.08B-12.6%
P/E10.5×-3.5×
P/S4.2×-1.5×

Profitability

See full
Gross margin89%+0.1pp
Operating margin47%-1.2pp
Net margin40.4%-0.5pp
FCF margin34.8%+1.2pp

Returns & leverage

See full
Return on equity19.3%0.0pp
Current ratio7.3×+2.9×

Segments

By product

See full
Tyvaso DPI$315.2M+22.0%
Nebulized Tyvaso$154.4M+10.4%
Remodulin$134.7M-8.6%
Orenitram$123.9M+15.7%
Unituxin$58.4M+13.0%

Versus estimates

Revenue

Q1 2026$781.5MMiss by $15.9MQ4 2025$790.2MMiss by $22.9MQ3 2025$799.5MMiss by $15.3M
Q2 2025$798.6MMiss by $3.3M
Q1 2025$794.4MBeat by $15.7MQ4 2024$735.9MBeat by $1.2M

Diluted EPS

Q1 2026$5.82Miss by $1.18Q4 2025$7.70Beat by $0.57Q3 2025$7.16Beat by $0.27
Q2 2025$6.41Miss by $0.88
Q1 2025$6.63Beat by $0.34Q4 2024$6.19Miss by $0.21

Ask the moment United Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did United Therapeutics report Q2 2025 earnings?
United Therapeutics (UTHR) reported Q2 2025 earnings on July 30, 2025 before market open.
What were United Therapeutics's Q2 2025 revenue and EPS?
United Therapeutics reported revenue of $798.6M and diluted EPS of $6.41 for Q2 2025.
Did United Therapeutics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $801.9M by $3.3M. EPS missed the consensus estimate of $7.29 by $0.88.
How did United Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 11.7% from $714.9M a year earlier and diluted EPS grew 9.6% from $5.85.
Where can I find United Therapeutics's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001628280-25-036541) directly on SEC EDGAR. The filing index links above go to sec.gov.